Clindamycin vaginal ovules are prescription 100 mg suppositories used for bacterial vaginosis. Each ovule is a dosage unit intended for the vaginal route. That distinguishes it from clindamycin vaginal cream expressed as 2%, vaginal gel in an applicator, and oral capsules that happen to carry a milligram strength.
U.S. Cleocin Vaginal Ovules labeling describes the suppository presentation and special precautions related to its oily base. In particular, latex or rubber condoms and diaphragms may be weakened within 72 hours after treatment. The interval and material warning should not be borrowed from the cream or Xaciato gel label.
This page focuses on the 100 mg vaginal suppository form: unit identity, packaging, route confirmation, pharmacy access and patient-label precautions. It is not an instruction to start a particular course without evaluation. For all vaginal clindamycin products, use the vaginal formulation hub; for product branding, use Cleocin Vaginal Ovules.
An ovule is a suppository designed for placement in the vagina. The “100 mg” strength identifies clindamycin in each labeled ovule, not the concentration of a tube of cream or gel. U.S. labeling describes Cleocin Vaginal Ovules as clindamycin phosphate suppositories for vaginal use.
This identity matters when searching pharmacy catalogs. Entries for oral clindamycin, rectal suppositories, topical gels or a 2% cream are not equivalents simply because they share an ingredient or similar numbers.
| Check | Vaginal ovule | Common confusion to avoid |
|---|---|---|
| Route | Vaginal suppository | Oral capsule |
| Unit strength | 100 mg per ovule | 2% cream or gel concentration |
| Presentation | Individual suppository units | Tube and applicators |
| Barrier warning | Latex/rubber restriction after treatment | Different Xaciato warning |
| Access | Valid prescription | Unverified OTC listing |
A single clindamycin ovule contains a labeled quantity of medication in a suppository base. By contrast, cream instructions describe the amount of a percentage-strength preparation delivered by an applicator. Those units may sound similar in a search result but are not a basis for switching drug forms.
The separate vaginal cream 2% page addresses tubes and applicators. Patients receiving ovules should verify that the pharmacy is supplying the correct suppository units and that all directions match the prescribed ovule product.
Vaginal ovules use a base that melts or dissolves as intended for the vaginal route. The base and physical unit help explain why the product has different instructions from a gel or cream. People should not adapt an oral capsule, topical product or another suppository in place of the prescription.
The relevant product leaflet covers storage, handling and what to do if a unit appears damaged or altered. When a dispensed ovule looks melted, opened or different from the expected package, ask the pharmacist before use instead of attempting to reshape or refrigerate it without instructions.
Cleocin Vaginal Ovules labeling warns that its oily base can weaken latex or rubber condoms and vaginal contraceptive diaphragms. The label states that use of such barrier products within 72 hours after treatment is not recommended. That warning matters for both contraception and infection prevention.
The interval should not be generalized to every vaginal clindamycin product. The conventional CLEOCIN Vaginal Cream label warns about latex/rubber barrier products during treatment and for 72 hours afterward; the distinct single-dose CLINDESSE cream label specifies five days after treatment. XACIATO vaginal gel has a separate polyurethane-condom warning during treatment and for seven days afterward. Ask a clinician or pharmacist about protection appropriate to the actual medicine.
The CDC includes clindamycin vaginal ovules among alternative BV treatment regimens. That classification does not mean patients should choose ovules instead of a recommended regimen based on packaging preference alone. The prescriber evaluates the diagnosis, previous treatment, contraindications and pregnancy concerns.
For those comparing the drug with another BV antibiotic, the clindamycin versus metronidazole page explains differences in clinical context, but does not authorize substituting one antibiotic for another.
Check the full medicine name, 100 mg unit strength, vaginal route, number of suppositories and manufacturer label. A pharmacist should be able to explain the actual product being dispensed. Packaging photographs and older brand names are not confirmation of current stock.
If the product is difficult to locate, ask the pharmacy to contact the prescriber rather than placing an order for cream or gel that appears under a similar ingredient heading. Our availability guide describes how to verify the precise dosage form.
Discharge, odor, irritation and pain can have multiple causes. A clinical assessment is important before vaginal antibiotic treatment and again if symptoms persist, recur or change. This is particularly relevant with fever, pelvic pain, unusual bleeding or pregnancy-related concerns.
A prior BV episode does not prove that a new episode has the same cause. The BV overview addresses clinical evaluation without turning this suppository product page into a self-diagnosis tool.
Clindamycin vaginal products can cause local symptoms, yeast overgrowth and, rarely, serious antibiotic-associated intestinal problems. People with clindamycin allergy, a relevant history of colitis or new severe diarrhea should discuss those matters promptly with a clinician.
Follow the label’s advice about intercourse, tampons or douching during treatment rather than applying instructions copied from a cream or gel package. A patient should have access to the pharmacist for questions about a suspected adverse effect or dispensing error.
CLEOCIN Vaginal Ovules labeling likewise contraindicates use in people with hypersensitivity to clindamycin, lincomycin, or formulation components and with histories of regional enteritis, ulcerative colitis, or antibiotic-associated colitis. This applies to the vaginal suppository even though its route and systemic absorption differ from oral clindamycin.
Cleocin Vaginal Ovules is a recognizable branded product family, but the brand name should not substitute for reading the underlying route, form and unit strength. Whether a pharmacy can supply a particular brand or another permissible product requires a current pharmacy check.
The Cleocin Vaginal Ovules brand page explores the product entity separately; this page remains focused on the 100 mg suppository family, the package and safe label matching.
clindamycin 100 mg vaginal ovules is a prescription vaginal product, not an over-the-counter skin treatment. A pharmacy needs to match the name or authorized generic, exact vaginal form, concentration, applicator configuration and prescriber instructions. The distinction between a cream, gel and ovule is clinically meaningful even when the product name contains clindamycin. See U.S. prescription requirements for the legal access framework.
Confirm that the prescribed package contains 100 mg vaginal suppository units rather than oral capsules or a cream delivering a different form of clindamycin. If a pharmacy proposes a different formulation, ask the dispensing pharmacist to contact the prescriber when needed. Consumers should not translate the percentage on one package into an unsupervised dose of another form. The availability verification guide explains how to inquire about a precise product without assuming any pharmacy has current stock.
Cleocin Vaginal Ovules labeling states that the oily suppository base may weaken latex or rubber condoms and diaphragms; using these barrier products within 72 hours after treatment is not recommended. This differs from the cream and gel warnings. Patients should follow the particular package instructions for intercourse, other vaginal products and barrier contraception. These restrictions differ among cream, gel and ovule formulations; advice borrowed from a different clindamycin product can be wrong.
With clindamycin 100 mg vaginal ovules, local administration does not eliminate the risk of antibiotic-associated diarrhea, including potentially serious C. difficile-associated illness. Severe or persistent diarrhea, bloody stools, marked abdominal pain or serious allergic symptoms warrant prompt clinical assessment. New fever, pelvic pain, bleeding or symptoms that do not fit a previously confirmed diagnosis should be assessed rather than repeatedly self-treated.
The number of ovules in the pack, brand-versus-generic status and pharmacy benefits affect cost, independently of a similarly named 100 mg delivered by a vaginal cream applicator. Payment varies with the precise brand or generic, applicator package, available supply, formulary coverage and whether the pharmacy can dispense the prescribed presentation. Product cost should never be estimated from a similarly named skin gel or oral capsule; the label and route must match.
Before accepting clindamycin 100 mg vaginal ovules, confirm the vaginal route, concentration, form, number of applicators or units, expiration, storage instructions and any contraceptive-barrier warning. For ways to evaluate payment without unreliable live price quotes, use vaginal clindamycin cost factors.
It is a prescription suppository containing clindamycin for vaginal use in BV care.
It identifies the labeled amount of clindamycin in each vaginal suppository unit.
No. Vaginal ovules are not oral capsules and must be used only by their prescribed route.
No. The forms, dosing units and instructions differ and require clinical review before any change.
Their oily base can weaken latex or rubber barriers; the Cleocin ovules label warns against use within 72 hours after treatment.
No. Xaciato has a different warning relating to polyurethane condoms and a seven-day period.
No. They are U.S. prescription medicines.
Ask the dispensing pharmacy how to handle a damaged or altered medicine; do not improvise a repair.
Verify the clindamycin vaginal route, 100 mg unit, number of suppositories, labeling and pharmacist instructions.